News

Photo

AGC Biologics Partners with Pfizer-BioNTech

AGC Biologics has agreed to supply plasmid DNA (pDNA) to Pfizer/BioNTech for their RNA-based Covid-19 vaccine. The biopharma CDMO based in Heidelberg, Germany, will manufacture the vaccine ingredient at its Heidelberg facility.

Photo

Exscientia Takes AI Specialist Allcyte

UK-based pharmatech Exscientia has entered into a binding agreement to buy Vienna-based Allcyte, a specialist in precision medicine using artificial intelligence (AI). Under the terms, Exscientia will pay €50 million, comprised of cash and Exscientia’s ordinary shares. The transaction is currently under review by Austrian regulators.

Photo

Element Solutions to Buy Coventya

Just weeks after spending $60 million buying UK electro-chemical producer H.K. Wentworth, Element Solutions has offered to acquire Coventya, a French international manufacturer of specialty chemicals used in surface treatment, from private equity owner Silverfleet Capital.

Photo

Trial Shows CureVac’s Covid Shot only 47% Effective

In a stunning setback to the company’s ambitions of launching its mRNA-based Covid-19 vaccine in the third quarter, results from CureVac’s Phase 2b/3 trial showed the candidate branded CVnCoV to have an efficacy rate of only 47% against any severity of the disease.

Photo

Wintershall Dea IPO Pushed Back Again

An initial public offering for Wintershall Dea, the oil and gas producer owned by BASF and Letter One – last planned for the second half of 2021 – will not take place this year, the partners announced on Jun. 16, citing an uncertain market.

Photo

Evonik Buys Spain’s Infinitec Activos

Evonik has entered into an agreement to buy Infinitec Activos, a privately owned Spanish company that specializes in the development and production of novel delivery systems for cosmetic active ingredients. Financial terms were not disclosed.

Photo

Bioplatform Innovator Raises Fresh Funding

Flagship Pioneering, the venture capital fund behind US Covid vaccine manufacturer Moderna and other biotechs, said it has raised an additional $2.23 billion for its fund no. 7 launched in April 2020, bringing the total value to $3.37 billion. Simultaneously, Flagship has announced the appointment of former US Food and Drug Administration (FDA) commissioner Stephen Hahn to its management team as chief medical officer.

Photo

Dow Plans MDI Plant in Texas, USA

Dow is planning to build an integrated methylene diphenyl diisocyanate (MDI) distillation and prepolymers plant at its site in Freeport, Texas, USA, to support rising demand from the downstream polyurethane (PU) sector.

Photo

EFSA and ECHA Preparing for 2022 Glyphosate Review

Two EU authorities, the European Food Safety Agency (EFSA) and the European Chemicals Agency (ECHA), are poised to begin reviewing a draft assessment of the safety of glyphosate. The license for the active ingredient in the Monsanto-developed Roundup herbicide comes up for renewal at the end of 2022, and the opinions will form the basis for a decision by the European Commission.

Photo

French CDMO Yposkesi Builds Second Bioproduction Site

Yposkesi, a French CDMO specializing in cell and gene therapies, has started building a second commercial bioproduction facility, known as project SKY. The plant is being designed to be cGMP- compliant with both European and US regulations. Operations are expected to start in 2023.

Photo

Indorama Developing US Oxides R&D Center

The Integrated Oxides & Derivatives (IOD) business of Indorama Ventures (IVL), Thailand-based global petrochemical producer best known as the world’s largest producer of PET resin, is developing a new technology center at The Woodlands, Texas.

Photo

Clariant to Merge Pigments with Heubach Group

In a somewhat unusually structured deal, Swiss specialty chemicals producer Clariant has reached a definitive agreement with a consortium of Heubach Group and private equity investor SK Capital Partners to unload most of its pigments business. Following completion of the transaction, expected in the first half of 2022, Clariant will reinvest in the business, taking a 20% share. The shares of the other partners have not been revealed.

Photo

Indian Oil Plans Petchems Plants at Vadodara

Indian state-owned oil and gas group Indian Oil Corp has entered into an agreement with the Gujarat government to build additional petrochemical plants at its refinery in Vadodara. Investment costs are estimated at $3.3 billion.

Photo

Eastman Sells Rubber Additives to One Rock

Eastman Chemical has agreed to sell several rubber additives lines and related technology assets of its tire additives business to an affiliate of One Rock Capital Partners for $800 million. The deal does not include the Impera and other performance resins product lines of the tire additives business, which accounted for 14% of the company’s 2020 sales of $8.47 billion.

Photo

Emergent Ruined 60 Million J&J Vaccine Doses

The (almost) worst-case scenario in the mix-up of Johnson & Johnson and AstraZeneca’s Covid-19 vaccine at the Baltimore, Maryland, plant of CDMO Emergent BioSolutions apparently has occurred. After an extensive FDA probe at the site, it was determined that around 60 million J&J doses will have to be discarded, the newspaper New York Times reported.

Photo

Cargill and Helm Link on Bio-based Intermediates

US food giant Cargill and German distribution and marketing group Helm have formed a joint venture called Qore to help brand owners replace fossil-based chemistries with bio-based intermediates. The size of their individual stakes in the jv was not revealed.

Photo

US to Donate Pfizer/BioNTech Vaccine to 100 Countries

As expected, US president Joe Biden, on his first international trip since taking office in January, announced plans to donate 500 million doses of the Pfize/BioNTech Covid-19 vaccine to around 100 countries over the next year. The plans were leaked by the newspaper Washington Post hours before the president’s departure with First Lady Jill Biden for the G7 summit in the UK.

Photo

BASF and Shanshan in Chinese Battery JV

BASF is forming a majority-owned 51:49 joint venture with Hunan Shanshan Energy to make cathode active materials (CAM) and their precursors (PCAM) in China, the world’s the largest battery materials market. The chemicals are a key component of lithium-ion batteries, which are in strong demand, thanks to the growing market for electric vehicles.

Photo

Topsoe Establishes Dedicated Green Hydrogen Arm

Denmark’s Haldor Topsoe has set up a dedicated green hydrogen arm with the aim of accelerating its electrolysis business. The newly formed organization will leverage Topsoe’s knowhow and expertise in solid oxide electrolysis, which it said produces up to 30% more green hydrogen from the same amount of renewable power than standard technologies.

Photo

IMCD Buys China’s Shanghai Yuanhe Chemicals

IMCD has acquired Shanghai Yuanhe Chemicals, a Chinese distributor of specialty coatings, textile and ink solutions. The deal boosts IMCD China's portfolio for the pharmaceutical, food and nutrition, plastics and personal care industries.

Photo

US Plans Public-Private Consortium for Drug “Onshoring”

As part of a multi-pronged effort to fix disruptions in crucial US industrial supply chains, President Joe Biden has announced that his administration will establish a public-private consortium to select 50 to 100 essential medicines from the Food and Drug Administration’s list to be the focus of an enhanced “onshoring effort" for pharmaceutical production.

Photo

Cambrex Upgrades Estonia Facility

US CDMO Cambrex has upgraded its facility in Tallin, Estonia. The installation of a new 160-liter reactor train at the kilogram-scale laboratory has expanded Cambrex’s capabilities to manufacture material for clinical trials and allow early-phase projects to be developed further prior to technical transfer and scale-up.

Photo

Supreme Court Rejects J&J’s Talc Appeal

The US Supreme Court has declined to hear Johnson & Johnson’ appeal against a $2 billion judgment in favor of 22 ovarian cancer sufferers who claimed they contracted the cancer from using the healthcare group’s talc products.

Photo

Bayer Acquires to Expand Prostate Cancer Pipeline

Bayer has announced plans to acquire Noria Therapeutics and PSMA Therapeutics, thereby obtaining exclusive rights to a differentiated alpha radionuclide investigational compound based on actinium-225 and a small molecule directed towards prostate-specific membrane antigen (PSMA).

Photo

Pembina to Buy Inter Pipeline

Pembina Pipeline has agreed to buy Inter Pipeline for about C$8.3 billion in an all-stock transaction that would create one of Canada’s biggest energy groups with a pro forma enterprise value of C$53 billion.

Photo

Catalent may Take up the Slack for AstraZeneca in US

After losing Emergent BioSolutions as a Covid-19 vaccine production partner, AstraZeneca has been looking for a new CDMO to fulfil its $1.2 billion contract with the US Biomedical Advanced Research and Development Authority (BARDA). Citing people familiar with the matter, the newspaper New York Times reports that the Anglo-Swedish drugmaker is now in talks with the US government about transferring dose manufacture to Catalent.

Photo

Lummus and Synthos Partner on Biobutadiene

Lummus Technology’s Green Circle business is working with Polish tire producer Synthos to commercialize the latter’s biobutadiene technology. In a first step, the companies will develop a feasibility study for a plant producing 20,000 t/y of biobutadiene, which will form the basis for an investment decision.

Photo

Moderna Mobilizes CDMOs for Covid Shot Ramp-up

As it ramps up production on three continents, US Covid-19 vaccine manufacturer Moderna is expanding its collaborations with CDMO suppliers in Europe, the US and Asia. At the beginning of June, the US biotech announced new supply agreements with Lonza and Thermo-Fisher. In late May, it inked new deals with Aldevron and Samsung Biologics in Asia to handle various stages of the mRNA shot’s production.

11169 more News

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing